Hologic Buys Interlace Medical, Acquires Missing Link In Gynecology Surgery
Gynecologists generally have the opportunity to perform in-office procedures for three indications: abnormal uterine bleeding, permanent contraception and uterine fibroids. Hologic had supplied its 460 medical device reps in the US - the largest force in women's health - with the tools to perform two of these procedures, but couldn't offer the third piece of the puzzle, an in-office treatment for fibroids, a gap which, until now, hasn't been filled by any product on the market. Hologic is filling in the missing piece with the acquisition of privately held Interlace Medical, a start-up developing MyoSure, a minimally invasive resection device for submucosal fibroids.
You may also be interested in...
Once a sluggish category for clinical innovation, gynecology is drawing new venture-backed companies eager to build upon the lead created by first-generation companies operating in minimally-invasive endometrial ablation and female sterilization. First generation companies had the difficult task of creating paths to early adopters of minimally invasive procedures. These now exist, and the clinical specialty appears to be also evolving in ways that encourage the growth of in-office procedures.
American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.